Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Gelderblom, Hans"'
Autor:
Haas, Rick, Stelmes, Jean-Jacques, Zaffaroni, Facundo, Sauvé, Nicolas, Clementel, Enrico, Bar-Deroma, Raquel, Le Péchoux, Cécile, Litière, Saskia, Marreaud, Sandrine, Alyamani, Najlaa, Andratschke, Nicolaus H J, Sangalli, Claudia, Chung, Peter W, Miah, Aisha, Hurkmans, Coen, Gronchi, Alessandro, Bovée, Judith V M G, Gelderblom, Hans, Kasper, Bernd, Weber, Damien Charles, Bonvalot, Sylvie
Publikováno v:
Cancer, 128(14), 2796-2805. WILEY
Background: The European Organization for Research and Treatment of Cancer 22092-62092 STRASS trial failed to demonstrate the superiority of neoadjuvant radiotherapy (RT) over surgery alone in patients with retroperitoneal sarcoma. Therefore, an RT q
Autor:
Heesen, Philip, Ranft, Andreas, Bhadri, Vivek, Brichard, Bénédicte, Collaud, Stephane, Cyprova, Sona, Eich, Hans-Theodor, Ek, Torben, Gelderblom, Hans, Havemann, Lianne, Hauser, Peter, Juergens, Heribert, Kanerva, Jukka, Kuehne, Thomas, Raciborska, Anna, Rascon, Jelena, Streitbuerger, Arne, Timmermann, Beate, Uhlenbruch, Yasmine, Dirksen, Uta
Publikováno v:
Journal of Clinical Oncology. 40:11531-11531
11531 Background: In patients with Ewing Sarcoma (EWS), adjuvant radiotherapy is often performed after surgery that could not obtain wide margins or after poor histological response to surgery. However, the benefit of adjuvant radiotherapy needs furt
Autor:
Heinrich, Michael C., Jones, Robin Lewis, Gelderblom, Hans, George, Suzanne, Schöffski, Patrick, von Mehren, Margaret, Zalcberg, John Raymond, Kang, Yoon-Koo, Abdul Razak, Albiruni Ryan, Trent, Jonathan C., Attia, Steven, Le Cesne, Axel, Su, Ying, Meade, Julie Nicole, Wang, Tao, Sherman, Matthew L., Ruiz-Soto, Rodrigo, Blay, Jean-Yves, Bauer, Sebastian
Publikováno v:
Journal of Clinical Oncology. 40:359881-359881
359881 Background: Sunitinib is approved for advanced gastrointestinal stromal tumor (GIST) after imatinib failure. Ripretinib, a broad-spectrum KIT and PDGFRA switch-control tyrosine kinase inhibitor (TKI), is indicated for the treatment of adult pa
Autor:
Lancia, Carlo, Anninga, Jakob K., Sydes, Matthew R., Spitoni, Cristian, Whelan, Jeremy, Hogendoorn, Pancras C.W., Gelderblom, Hans, Fiocco, Marta, Sub Mathematical Modeling, Mathematical Modeling
Publikováno v:
Cancer Chemotherapy and Pharmacology, 83, 951-962
Cancer Chemotherapy and Pharmacology, 83, 5, pp. 951-962
Cancer Chemotherapy and Pharmacology, 83, 951. Springer Verlag
Cancer Chemotherapy and Pharmacology, 83(5), 951-962
Cancer Chemotherapy and Pharmacology, 83, 5, pp. 951-962
Cancer Chemotherapy and Pharmacology, 83, 951. Springer Verlag
Cancer Chemotherapy and Pharmacology, 83(5), 951-962
Purpose: There is lack of consensus on the prognostic value of received high dose intensity in osteosarcoma survivorship. Many studies have not shown a clear survival benefit when dose intensity is increased. The aim of this study is to go beyond che
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc27d41c0aea26e45f8561ec58dd4f30
https://hdl.handle.net/1887/121132
https://hdl.handle.net/1887/121132
Autor:
Lunenburg, Carin A T C, Henricks, Linda M, Guchelaar, Henk-Jan, Swen, Jesse J, Deenen, Maarten J, Schellens, Jan H M, Gelderblom, Hans, Sub Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
European Journal of Cancer, 54, 40-48
European Journal of Cancer, 54, 40. Elsevier Ltd
European Journal of Cancer, 54, 40. Elsevier Ltd
5-Fluorouracil (5-FU) and capecitabine (CAP) are among the most frequently prescribed anticancer drugs. They are inactivated in the liver by the enzyme dihydropyrimidine dehydrogenase (DPD). Up to 5% of the population is DPD deficient and these patie
Autor:
Lunenburg, Carin A T C, Henricks, Linda M, Dreussi, Eva, Peters, Femke P, Fiocco, Marta, Meulendijks, Didier, Toffoli, Giuseppe, Guchelaar, Henk-Jan, Swen, Jesse J, Cecchin, Erika, Schellens, Jan H M, Gelderblom, Hans, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
European Journal of Cancer, 104, 210. Elsevier Ltd
Background Prospective DPYD genotyping prevents severe fluoropyrimidine (FP)-induced toxicity by decreasing dosages in DPYD variant allele carriers. FP dosages in chemoradiation therapy (CRT) are lower than those in other FP-containing regimens. Phar
Autor:
Rutkowski, Piotr, Gaston, Louie, Borkowska, Aneta, Stacchiotti, Silvia, Gelderblom, Hans, Baldi, Giacomo Giulio, Palmerini, Emanuela, Casali, Paolo, Gronchi, Alessandro, Parry, Michael, Campanacci, Domenico Andrea, Scoccianti, Guido, Wagrodzki, Michal, Ferrari, Stefano, Dijkstra, Sander, Pieńkowski, Andrzej, Grimer, Robert
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______310::93b80a63fbc9c3fffe04e4cfd28f26bc
http://hdl.handle.net/2158/1148273
http://hdl.handle.net/2158/1148273
Autor:
Casali, Paolo G., Blay, Jean Yves, Bertuzzi, Alexia, Bielack, Stefan, Bjerkehagen, Bodil, Bonvalot, Sylvie, Boukovinas, Ioannis, Bruzzi, Paolo, Tos, Angelo Paolo Dei, Dileo, Palma, Eriksson, Mikael, Fedenko, Alexander, Ferrari, Andrea, Ferrari, Stefano, Gelderblom, Hans, Grimer, Robert, Gronchi, Alessandro, Haas, Rick, Hall, Kirsten Sundby, Hohenberger, Peter, Issels, Rolf, Joensuu, Heikki, Judson, Ian, Cesne, Axel Le, Litière, Saskia, Martin Broto, Javier, Merimsky, Ofer, Montemurro, Michael, Morosi, Carlo, Picci, Piero, Ray Coquard, Isabelle, Reichardt, Peter, Rutkowski, Piotr, Schlemmer, Marcus, Stacchiotti, Silvia, Torri, Valter, Trama, Annalisa, Van Coevorden, Frits, Van der Graaf, Winette, Vanel, Daniel, Wardelmann, Eva, Bolle, Stephanie, Capanna, Rodolfo, Delaney, Thomas, Doglietto, Francesco, Fossati, Piero, Jeys, Lee, Kasper, Bernd, Leithner, Andreas, Norum, Ole Jacob, Radaelli, Stefano, Scheipl, Susanne, Tamborini, Elena, Uhl, Mathias, Vleggert Lankamp, Carmen L. A.
Publikováno v:
Annals of Oncology, 25 Suppl 3, iii113-23
Annals of Oncology, 25 Suppl 3, pp. iii113-23
Annals of Oncology, 25 Suppl 3, pp. iii113-23
Contains fulltext : 139063.pdf (Publisher’s version ) (Closed access)
Autor:
Lancia, Carlo, Anninga, Jakob, Spitoni, Cristian, Sydes, Matthew R., Whelan, Jeremy, Hogendoorn, Pancras C.W., Gelderblom, Hans, Fiocco, Marta, Sub Mathematical Modeling, Mathematical Modeling
Publikováno v:
BMJ Open, 9(5). BMJ Publishing Group Ltd
BMJ Open
BMJ Open, 9(5)
BMJ Open
BMJ Open, 9(5)
ObjectivesIn cancer studies, the target received dose intensity (tRDI) for any regimen, the intended dose and time for the regimen, is commonly taken as a proxy for achieved RDI (aRDI), the actual individual dose and time for the regimen. Evaluating
Autor:
Reichardt, Peter, Kang, Yoon-Koo, Rutkowski, Piotr, Schuette, Jochen, Rosen, Lee S., Seddon, Beatrice, Yalcin, Suayib, Gelderblom, Hans, Williams, Charles C, Jr., Fumagalli, Elena, Biasco, Guido, Hurwitz, Herbert I., Kaiser, Pamela E., Fly, Kolette, Matczak, Ewa, Chen, Liang, Lechuga, Maria Jose, Demetri, George D.
BACKGROUNDThe objectives of this study were to provide sunitinib to patients with gastrointestinal stromal tumor (GIST) who were otherwise unable to obtain it and to collect broad safety and efficacy data from a large population of patients with adva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4268::88c01a13061cab5cde9a42ad041b77f0
http://hdl.handle.net/11655/14932
http://hdl.handle.net/11655/14932